Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs

Trial Profile

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PALACE-4
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 15 Nov 2023 Results assessing the effects of apremilast on cardiometabolic parameters over 52 weeks in patients with active psoriatic arthritis from 5 studies PALACE 1-4 and ACTIVE, presented at the ACR Convergence 2023.
    • 03 Jun 2023 Results of pooled analysis (n=781 from studies PALACE 1 to 4 and ACTIVE) assessing the effects of APR on cardiometabolic parameters over 52 weeks in patients with active psoriatic arthritis presented at the 24th Annual Congress of the European League Against Rheumatism
    • 30 May 2023 Results presented in an Amgen Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top